GMMA Is a Versatile Platform to Design Effective Multivalent Combination Vaccines.

Vaccines (Basel) 2020 Sep 17;8(3). Epub 2020 Sep 17.

GSK Vaccines Institute for Global Health (GVGH) S.r.l., 53100 Siena, Italy.

Technology platforms are an important strategy to facilitate the design, development and implementation of vaccines to combat high-burden diseases that are still a threat for human populations, especially in low- and middle-income countries, and to address the increasing number and global distribution of pathogens resistant to antimicrobial drugs. Generalized Modules for Membrane Antigens (GMMA), outer membrane vesicles derived from engineered Gram-negative bacteria, represent an attractive technology to design affordable vaccines. Here, we show that GMMA, decorated with heterologous polysaccharide or protein antigens, leads to a strong and effective antigen-specific humoral immune response in mice. Importantly, GMMA promote enhanced immunogenicity compared to traditional formulations (e.g., recombinant proteins and glycoconjugate vaccines), without negative impact to the anti-GMMA immune response. Our findings support the use of GMMA as a "plug and play" technology for the development of effective combination vaccines targeting different bugs at the same time.

Download full-text PDF

Source
http://dx.doi.org/10.3390/vaccines8030540DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564227PMC
September 2020

Publication Analysis

Top Keywords

combination vaccines
8
immune response
8
vaccines
5
gmma
5
gmma decorated
4
vaccines gmma
4
design affordable
4
affordable vaccines
4
decorated heterologous
4
polysaccharide protein
4
strong effective
4
effective antigen-specific
4
antigen-specific humoral
4
leads strong
4
antigens leads
4
technology design
4
protein antigens
4
heterologous polysaccharide
4
represent attractive
4
antigens gmma
4

Similar Publications

Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal .

Proc Natl Acad Sci U S A 2018 10 27;115(41):10428-10433. Epub 2018 Sep 27.

Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, United Kingdom.

Nontyphoidal cause a devastating burden of invasive disease in sub-Saharan Africa with high levels of antimicrobial resistance. Vaccination has potential for a major global health impact, but no licensed vaccine is available. The lack of commercial incentive makes simple, affordable technologies the preferred route for vaccine development. Read More

View Article and Full-Text PDF
October 2018

Effect of O-Antigen Chain Length Regulation on the Immunogenicity of and Generalized Modules for Membrane Antigens (GMMA).

Int J Mol Sci 2021 Jan 28;22(3). Epub 2021 Jan 28.

GSK Vaccines Institute for Global Health (GVGH) s.r.l, Via Fiorentina 1, 53100 Siena, Italy.

Recently, generalized modules for membrane antigens (GMMA) technology has been proposed as an alternative approach to traditional glycoconjugate vaccines for O-antigen delivery. Saccharide length is a well-known parameter that can impact the immune response induced by glycoconjugates both in terms of magnitude and quality. However, the criticality of O-antigen length on the immune response induced by GMMA-based vaccines has not been fully elucidated. Read More

View Article and Full-Text PDF
January 2021

Characterization of O-antigen delivered by Generalized Modules for Membrane Antigens (GMMA) vaccine candidates against nontyphoidal Salmonella.

Vaccine 2017 01 18;35(3):419-426. Epub 2016 Dec 18.

GSK Vaccines Institute for Global Health (GVGH) S.r.l. (former Novartis Vaccines Institute for Global Health, NVGH), Via Fiorentina 1, 53100 Siena, Italy. Electronic address:

Invasive nontyphoidal Salmonella disease (iNTS) is a leading cause of death and morbidity in Africa. The most common pathogens are Salmonella enterica serovars Typhimurium and Enteritidis. The O-antigen portion of their lipopolysaccharide is a target of protective immunity and vaccines targeting O-antigen are currently in development. Read More

View Article and Full-Text PDF
January 2017

GMMA and Glycoconjugate Approaches Compared in Mice for the Development of a Vaccine against Serotype 6.

Vaccines (Basel) 2020 Apr 3;8(2). Epub 2020 Apr 3.

GSK Vaccines Institute for Global Health (GVGH) S.r.l., via Fiorentina 1, 53100 Siena, Italy.

infections are one of the top causes of diarrhea throughout the world, with being predominant in developing countries. Currently, no vaccines are widely available and increasing levels of multidrug-resistance make a high priority for vaccine development. The serotype-specific O-antigen moiety of lipopolysaccharide has been recognized as a key target for protective immunity, and many O-antigen based candidate vaccines are in development. Read More

View Article and Full-Text PDF
April 2020